SheMed’s patient-friendly testing program, which integrates the Tasso+ blood collection device, ensures that every patient completes a comprehensive lab screening before starting GLP-1 treatment, all from the comfort of home. The program has already treated thousands of women across the UK. 

For decades, women have been underrepresented in clinical trials. As a result, many treatments have been developed based on male physiology, leading to a one-size-fits-all approach that often overlooks women’s specific health needs. Although GLP-1s have transformed the weight loss landscape, many women begin treatment without a full picture of their underlying health, increasing the risk of complications and limiting results. 

“For too long, women have been left out of the conversation when it comes to clinical care,” said Olivia Ferro, CEO of SheMed. “At SheMed, our mission is to empower women to take control of their health through safe, accessible, and personalized treatment. Tasso gives our customers access to high-quality at-home blood testing, allowing us to deliver care that meets women where they are.”